No “Constraining Situation” On gVascepa API Says Strides MD, Q3 Revenues Jump
gSuprep Likely To Be Launched In Q4
Strides intends to keep US momentum going with Amneal-partnered generic Vascepa, where Hikma and Dr. Reddy’s have filed antitrust suits against Amarin over API supply. Meanwhile, the founder re-iterated ambitious goals set for Stelis and its CDMO business
You may also be interested in...
Strides expects to meet an earlier forecast $250m in FY24 US revenues via new product launches and sees peak revenues of $300m from CDMO partners for GLP-1 products. Meanwhile, it has sold a deactivated Singapore facility at a net loss, ending up with an overall loss of $18m in the fiscal second quarter.
Biocon subsidiary Syngene and Strides associate Stelis have entered a deal with the potential to change India’s vaccines and biologics landscape, as the former's growth plans are catapulted. Meanwhile, the Strides group gets to cut debt by selling a unit that made the ill-fated Sputnik Light COVID-19 vaccine and after Akston Biosciences terminated another COVID-19 vaccine alliance
Zydus, the only Indian company with an NCE for a range of chronic liver diseases, will add Turkey to the list of trial locations for NASH. It is also working “aggressively” to launch a generic to Amarin’s Vascepa after Revlimid and Trokendi generics drove record US sales in the fourth quarter